] was a double-blind, double-dummy, randomized phase 3 clinical trial that assessed the efficacy and safety of the once-a-week subcutaneous GLP-1 RA semaglutide, in doses of 2.4 mg vs. 1.0 mg vs. placebo, for weight management in adults with T2D and overweight or obesity. This evidence concerns the gene GLP1R and Obesity.